SCHEMBL499008

SCHEMBL499008

CNCCC1(CCCCOC)NC(=O)c2ccc(Cl)cc21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 1/20 0.35
ALPL P05186 1/20 0.34
NPC1 O15118 1/20 0.33
HTT P42858 3/20 0.33
MAPK1 P28482 2/20 0.33
LMNA P02545 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
CYP1A2 P05177 1/20 0.33
HPGD P15428 1/20 0.33
CYP2C19 P33261 1/20 0.33
AKR1A1 P14550 1/20 0.33
AKR1B1 P15121 1/20 0.33
PPOX P50336 1/20 0.32
KDM4E B2RXH2 2/20 0.32
ALDH1A1 P00352 2/20 0.32
PSEN1 P49768 1/20 0.32
PSEN2 P49810 1/20 0.32
APH1B Q8WW43 1/20 0.32
NCSTN Q92542 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL499001 0.87 AKR1A1 (0.33) HPGDAKR1A1AKR1B1KDM4EALDH1A1
SCHEMBL499012 0.87 AKR1A1 (0.33) HPGDAKR1A1AKR1B1KDM4EALDH1A1
SCHEMBL499002 0.87 AKR1A1 (0.33) HPGDAKR1A1AKR1B1KDM4EALDH1A1
SCHEMBL499154 0.84 SMN1; SMN2 (0.38) CES1ALPLSMN1; SMN2
SCHEMBL499153 0.84 SMN1; SMN2 (0.38) CES1ALPLSMN1; SMN2
SCHEMBL499085 0.82 KDM4E (0.36) CES1MEN1KMT2ACYP1A2HPGD
SCHEMBL499359 0.81 CES1 (0.35) CES1ALPLHTTLMNAAKR1A1
SCHEMBL499563 0.78 CES1 (0.35) CES1CYP1A2HPGDCYP2C19AKR1A1
SCHEMBL499562 0.78 CES1 (0.35) CES1CYP1A2HPGDCYP2C19AKR1A1
SCHEMBL4755969 0.77 HTT (0.34) HTTMAPK1LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106221-B2 Renin inhibitors VITAE PHARMACEUTICALS, INC. (US) 2012-01-31 US disclosed
US-8106221-B2 Renin inhibitors VITAE PHARMACEUTICALS, INC. (US) 2012-01-31 US disclosed
US-8106221-B2 Renin inhibitors VITAE PHARMACEUTICALS, INC. (US) 2012-01-31 US disclosed
US-20100144825-A1 Renin Inhibitors VITAE PHARMACEUTICALS, INC. 2010-06-10 US disclosed
US-20100144825-A1 Renin Inhibitors VITAE PHARMACEUTICALS, INC. 2010-06-10 US disclosed
US-20100144825-A1 Renin Inhibitors VITAE PHARMACEUTICALS, INC. 2010-06-10 US disclosed
WO-2008156816-A2 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2008-12-24 WO disclosed
WO-2008156816-A2 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144825-A1 Renin Inhibitors ACE, REN, DNPEP CES1 275/4885ALPL 374/4885NPC1 898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.